SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported) November 4, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-23265 | 94-3267443 | |
(Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (919) 862-1000
Item 5. | Other Events and Regulation FD Disclosure |
On November 4, 2003, Salix Pharmaceuticals, Ltd. issued a press release announcing that it had acquired from aaiPharma LLC the exclusive right to sell Azasan® in North America. A copy of this press release is attached.
Item 7. | Financial Statements and Exhibits. |
(c) Exhibits
Exhibit No. | Description | |
99.1 | Press release dated November 4, 2003 of Salix Pharmaceuticals, Ltd., announcing that it had acquired from aaiPharma LLC the exclusive right to sell Azasan® in North America. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||||||||
Date: November 4, 2003 | By: | /s/ Adam C. Derbyshire | ||||||
Adam C. Derbyshire | ||||||||
Senior Vice President and Chief Financial Officer |